

VIVALIS ANNOUNCES A NEW EB66[®] CELL LINE RESEARCH SERVICES AND LICENSE OPTION AGREEMENT WITH GLAXOSMITHKLINE

Nantes & Lyon (France) – April 8th, 2013 – VIVALIS (NYSE Euronext: VLS) announced today that it has signed an EB66[®] cell line research services and license option agreement with GlaxoSmithKline (“GSK”) to establish the feasibility of producing a new viral vaccine against an important viral disease using EB66[®] with an option to license EB66[®] cell line for similar viruses of the same family.

This is the second EB66[®] cell line agreement with GSK following the agreement in 2007 on the development of influenza vaccines using the EB66[®] cell line.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, *“we are very pleased to enter into a research service agreement to establish the feasibility of a manufacturing a vaccine candidate to address a currently unmet medical need.”*

Financial terms of the agreement were not disclosed.

**Next financial press release: 2013 first-quarter sales
25 April 2013, after NYSE Euronext market closing**

About VIVALIS (www.vivalis.com)

Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of pathologies with unmet medical needs. Vivalis’ expertise and intellectual property are leveraged in two main areas:

1. EB66[®] Cell Line

Vivalis offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, with a focus on monoclonal antibodies having enhanced cytotoxic activity. Clinical trials of EB66[®] produced vaccines are currently on-going in the USA and Japan. Through these programs, Vivalis receives upfront payments, clinical stage milestone payments and royalties on licensees’ net sales.

2. VIVAIScreen™ Human Antibody Discovery Platform

Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery phase, upfront payments, clinical stage milestone payments, and royalties on net sales of licensed antibodies that are commercially developed and sold by our clients.

Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Grimaud Group (ca. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Zoetis, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

VIVALIS

Listed on Euronext Paris – Compartment B of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document E, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr